HR Thought Leader Josh Bersin Joins Virgin Pulse CEO Advisory Board
PROVIDENCE, R.I., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Virgin Pulse, the largest global employee health and wellbeing company, today announced that renowned HR technology analyst and influencer Josh Bersin, has joined Virgin Pulse’s CEO Advisory Board.
In this capacity, Bersin will collaborate with Virgin Pulse CEO, David Osborne, and senior Virgin Pulse leaders to expand awareness of the critical role employee health and wellbeing plays in driving employee engagement, productivity and business performance. He will also advise the company on messaging, positioning and product strategy to ensure alignment with the strategic needs of global CHROs and business leaders.
Bersin is a globally renowned research and technology analyst, public speaker and writer covering all aspects of corporate human resources. The founder of Bersin™ by Deloitte, a leading provider of research-based membership programs in HR, his expertise spans talent management, recruiting, leadership, technology, employee engagement and the intersection between work and life. Bersin is a frequent speaker at major industry conferences and a regular contributor to HR Executive, CLO, and Forbes.com.
“We are thrilled to welcome Josh Bersin to the Virgin Pulse CEO Advisory Board,” said David Osborne, CEO of Virgin Pulse. “A prolific HR analyst, researcher and writer, Josh is widely respected by CHROs around the world. He brings deep expertise and a forward looking-perspective on HR that will help ensure our solutions are aligned with the goals and priorities of HR leaders. Working with Josh, we will continue to shift the employee wellbeing conversation from one that has focused on episodic interventions and cost-containment, to one that is increasingly focused on the benefits of healthy workplace cultures, daily engagement and employee happiness, all of which drive business results.”
“I am honored to be working with the Virgin Pulse executive team. Employee health and wellbeing are topping HR priority lists across the globe. Employees are feeling stressed, digitally overwhelmed, working more hours than ever before and sleeping less. At the same time, they are becoming more vocal about their health and wellbeing needs and are seeking solutions and support from their workplaces to help them manage these issues,” said Bersin. “This is a wonderful mission for HR departments to champion. I look forward to helping HR leaders navigate this market and unlock the business value of employee health and wellbeing.”
As a featured speaker at Virgin Pulse’s Thrive Summit conference this May in New Orleans, Bersin will share real-world examples of how investments in employee wellbeing are delivering value beyond physical health and driving stronger employee engagement, retention and performance across global workforces.
About Virgin Pulse
Virgin Pulse is the world’s largest, most comprehensive digital health, wellbeing and engagement company. Focused on driving personalized behavior change and results for individuals and organizations around the world, the company delivers the industry’s only fully integrated digital platform, with benefits navigation and live coaching to support global clients and members across the entire health, wellbeing and benefits lifecycle—from screening and assessment to activation, behavior change and the adoption of sustainable healthy habits. By helping employees thrive at work and in all aspects of life, Virgin Pulse helps change lives and businesses for good, across more than 190 countries. Over 3,300 organizations around the world, representing many of the Fortune 500 and Best Places to Work, rely on Virgin Pulse solutions to engage their workforces and drive their businesses forward. To learn more, visit Virgin Pulse and follow us on Twitter or LinkedIn.
703 622 3605
For Josh Bersin:
Linda K. Galloway
303 863 8620
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6b049562-296d-4b99-9296-9e9b81c9c066.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00 | Pressemelding
BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t
CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00 | Pressemelding
TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos
Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00 | Pressemelding
Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00 | Pressemelding
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated
GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12 | Pressemelding
SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no
Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00 | Pressemelding
OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist